Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 20/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17874080 | 0.87 | MKNK1 (0.57) | MKNK1 | |
| SCHEMBL15972880 | 0.87 | MKNK1 (0.66) | MKNK1 | |
| SCHEMBL15973610 | 0.85 | MKNK1 (0.66) | MKNK1 | |
| SCHEMBL15973609 | 0.81 | MKNK1 (0.66) | MKNK1 | |
| SCHEMBL3865634 | 0.80 | MKNK1 (0.68) | MKNK1 | |
| SCHEMBL19412901 | 0.80 | MKNK1 (0.79) | MKNK1 | |
| SCHEMBL14764379 | 0.80 | MKNK1 (0.76) | MKNK1 | |
| SCHEMBL3868147 | 0.79 | MKNK1 (0.70) | MKNK1 | |
| SCHEMBL14763715 | 0.79 | MKNK1 (0.76) | MKNK1 | |
| SCHEMBL14763955 | 0.78 | MKNK1 (0.76) | MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | claimed |
| EP-2958920-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | claimed |
| WO-2014128093-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | claimed |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-2958920-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014128093-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014128093-A1 | SUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AS MKNK1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287589-A1 | SUBSTITUTED-IMIDAZOPYRIDAZINES | CCNI, F12, MKI67 | MKNK1 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.